Profectus begins Phase I trial of VesiculoVax-vectored vaccine to treat Ebola

Clinical-stage vaccine company Profectus BioSciences has started its Phase I trial of its VesiculoVax-vectored vaccine to treat Ebola.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news